The biopharmaceutical developer confirmed Thursday that its drug conjugate is undergoing evaluation across four distinct patient populations. While the head and neck cancer group has officially transitioned to the next phase of the trial design, enrollment remains active and on schedule for the remaining cohorts, which include individuals battling endometrial cancer, melanoma, and soft tissue sarcoma.